01856nas a2200181   4500008003900000245013300039210006900172260000800241300001100249490000700260520128800267100001301555700001501568700001701583700001501600700001401615856004501629       2018                          d00aDonor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee0 aDonorderived hepatitis C in the era of increasing intravenous dr  cOct  ae133700 v323 aThe opioid epidemic has resulted in a potential increase in donors in the testing window period for hepatitis C virus (HCV). We analyzed HCV reports to the Disease Transmission Advisory Committee (DTAC) between 2008 and 2016 to estimate the risk of HCV transmission. In 15 of 95 (16%) reports, at least one recipient developed proven/probable donor-derived HCV resulting in 32 infected recipients. Seven transmissions occurred during the nucleic acid testing (NAT) window period; four occurred during serological window period. The other four transmission occurred due to human error (3) and false-negative serology (1). All seronegative-exposed liver and lung recipients contracted HCV; 18/21 (86%) kidney and 3/4 (75%) heart recipients developed HCV. Four transmitting donors died of intravenous drug overdose, three in 2016 and one in 2012. Among donors with a history of intravenous drug use (IVDU), drug intoxication as a mechanism of death, or increased risk status, and negative screening HCV testing, the risk of transmission to a recipient was about 1 in 1000. The overall risk of transmitting HCV from NAT-negative donors with IVDU is low and consistent with modeling data. This information may be helpful to clinicians counseling potential recipients offered these organs.1 aKaul, DR1 aTlusty, SM1 aMichaels, MG1 aLimaye, AP1 aWolfe, CR  uhttp://613633.bywedr.asia/reference/4803